RCKT Stock Rocket Pharmaceuticals, Inc.
US · NasdaqGMLast in our picks 2026-09-22 — not in the current list; analysis below is from that screen
Battery-material conversion story offers upside if Europe-North America strategic interest returns.
Future value: $8.85 (+170.77%) · 6-12 months · analyst consensus
Signal breakdown
- ▸Early-stage catalyst story needs confirmation before aggressive accumulation.
- ▾Below 50-day MA (-6.35%)
- ▸~171% upside to price target
Is RCKT a buy right now?
Trend: RCKT is trading below the 50-day average (-25.00%), RSI 70 — neutral momentum, with a 3-month return of -27.39%.
Valuation & quality: Rocket Pharmaceuticals, Inc. trades on forward P/E -1.8, price-to-book 0.68; fundamentals show net margin 0.0%, return on equity -4.8%.
Analyst consensus: 12 analysts have a mean 12-month price target of $8.58 (+276.3% vs the last close; range $2.95 – $15.00), consensus rating “buy”.
Our screen: ACCUMULATE (score 1) — Battery-material conversion story offers upside if Europe-North America strategic interest returns.
Computed from end-of-day data; not personal advice.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| -28.50% | -2.80% | -11.80% | +11.40% | -9.10% | +19.60% | -29.30% | -13.30% |
Fundamentals
Analyst price target
Technical signals
About Rocket Pharmaceuticals, Inc.
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing, manufacturing, and selling of genetic therapies for rare and devastating diseases in the United States.
Sector: Healthcare · Industry: Biotechnology · United States · 202 employees · Website
Related Mining & Lithium picks
Browse: all US stocks · Mining & Lithium picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.